Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

APR-1051

Small molecule · Inhibitor of Wee1-like protein kinase (WEE1) · developed by Aprea Therapeutics

Phase 1 Most advanced trial
APRE Developer
1 Registered trials

What is APR-1051?

APR-1051 is an orally bioavailable small molecule that inhibits the tyrosine kinase Wee1. Wee1 inhibition reduces phosphorylation of CDK1 and CDK2, pushing cells into premature mitosis with unrepaired DNA damage and apoptosis, particularly in p53-deficient or CCNE1-overexpressing tumor cells. It is being studied in advanced solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
Wee1-like protein kinase (WEE1), cyclin-dependent kinase 1 (CDK1) (secondary target), cyclin-dependent kinase 2 (CDK2) (secondary target)
Mechanism
Inhibitor of Wee1-like protein kinase (WEE1)
Pathways
cell cycle G2/M checkpoint, G1/S progression, DNA damage response, apoptosis
Therapy area
Oncology
Developer
Aprea Therapeutics (APRE)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06260514 Phase 1 Advanced Solid Tumor Recruiting APRE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid Tumor

Other drugs acting on WEE1

ACR-2316 Phase 1/2 Adavosertib Phase 2 Potrasertib Investigational

More from Aprea Therapeutics

APR-548 Phase 1 ATRN-119 Phase 1/2 Eprenetapopt Phase 3

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the APRE page.

Follow APRE, the company behind APR-1051

See APRE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

APRE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.